Burney Company’s Myriad Genetics MYGN Stock Holding History

Burney Company’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,735	Closed	-$217K	–	595
2021 Q3	$217K	Buy	+6,735	New	+$224K	0.01%	543

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Burney Company's MYGN Position: Q4 2021 in Review

Burney Company sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 6,735 shares — an estimated $217K sold.

Burney Company first reported a position in MYGN in Q3 2021 and held it in 1 quarter. The position peaked at $217K in Q3 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.

Burney Company reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
Burney Company sold 6,735 Myriad Genetics shares in Q4 2021, an estimated $217K.
Burney Company first reported a position in Myriad Genetics in Q3 2021 and held it in 1 quarter.
Burney Company's Myriad Genetics position peaked at $217K in Q3 2021.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.

Based on Burney Company's 13F filing for Q4 2021, filed 11 Feb 2022.